EXCLUSIVE INSIGHT: China To Clarify MRCT Regulatory Pathway Soon
This article was originally published in PharmAsia News
One year after breaking the story of China starting a review of the widely used multiregional clinical trial pathway, PharmAsia News talks to regulatory affairs insiders to unearth coming changes that will have far-reaching effects on R&D-based drug firms in the country.
You may also be interested in...
China insurance giant snatches up stakes in Japanese pharma and a traditional Chinese medicines maker with a $465m spending spree.
With vaccines perhaps the ultimate weapon to fight the coronavirus, a developer in China sees a big chunk of investment with potentially more companies to see funding coming.
Which drug candidates represent hope, and which hype? The Scrip team examine the COVID-19 pipeline, lessons from China, and some long term impacts on the sector.